CEL-SCI (NYSE:CVM) Trading Down 4.4% – Time to Sell?

CEL-SCI Co. (NYSE:CVM) fell 4.4% during mid-day trading on Monday . The stock traded as low as $0.69 and last traded at $0.70. 570,844 shares were traded during trading, a decline of 10% from the average session volume of 636,752 shares. The stock had previously closed at $0.73.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of CEL-SCI from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th.

CEL-SCI Trading Up 0.3 %

The stock’s fifty day moving average price is $0.72 and its 200 day moving average price is $1.01. The stock has a market cap of $44.66 million, a P/E ratio of -1.21 and a beta of 0.59. The company has a current ratio of 0.64, a quick ratio of 0.18 and a debt-to-equity ratio of 1.00.

Institutional Trading of CEL-SCI

Hedge funds have recently made changes to their positions in the stock. Cutter & CO Brokerage Inc. raised its position in shares of CEL-SCI by 29.4% in the 2nd quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock worth $126,000 after purchasing an additional 24,634 shares during the last quarter. Thoroughbred Financial Services LLC increased its stake in CEL-SCI by 140.9% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock valued at $158,000 after purchasing an additional 80,001 shares in the last quarter. Black Diamond Financial LLC raised its holdings in CEL-SCI by 35.8% in the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after buying an additional 19,000 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of CEL-SCI by 29.9% in the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after buying an additional 40,000 shares in the last quarter. Finally, Calton & Associates Inc. bought a new position in shares of CEL-SCI in the third quarter worth approximately $50,000. 12.08% of the stock is owned by institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.